MedPAC's Drug Price Solution May Be a Problem in Disguise
Over the past 3 years, there has been a growing chorus of
complaint about the rising costs of medications, particularly in
The OCM Has Been Challenging, But Effective
There is a lack of hard data on practice performance that makes it difficult to understand where to make improvements so that goals under the OCM can be reached.
How a Northwestern Practice Gained by Accepting Patients of All Means
Cancer Care Northwest made a successful bet on going fully independent and became a dominant provider in its market.
Clinical Data Can Mislead Without Meaningful Analysis
CMS has put so much emphasis on reported data that it is now paramount for oncology practices to understand how data should be sifted and interpreted to arrive at meaningful conclusions.
Administrators Say OCM Monthly Payments Won't Cover Costs of Improved Care
Practices in CMS’ Oncology Care Model are individually receiving hundreds of thousands of dollars in new annual revenue, but physicians and administrators are not exactly celebrating the influx of cash.
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL
2 Clarke Drive Cranbury, NJ 08512